Josselsohn Alyssa, Zhao Yin, Espinoza Danielle, Hollander Eric
Albert Einstein College of Medicine, Montefiore Medical Center, 1225 Morris Park Avenue Bronx, NY 10461, USA; Temple University, College of Education and Human Development, 1301 Cecil B. Moore Ave, Philadelphia, PA 19122, USA.
Albert Einstein College of Medicine, Montefiore Medical Center, 1225 Morris Park Avenue Bronx, NY 10461, USA.
Pharmacol Ther. 2024 Dec;264:108734. doi: 10.1016/j.pharmthera.2024.108734. Epub 2024 Oct 23.
This manuscript reviews recent work on oxytocin and its use in neurodevelopmental disorders including spectrum disorder (ASD) and Prader-Willi syndrome (PWS). Oxytocin is involved in social recognition, bonding, maternal behaviors, anxiety, food motivation, and hyperphagia. While the pathophysiology of ASD and PWS involve abnormalities in the oxytocin system, clinical trials have shown discrepant results in the effectiveness of oxytocin as a treatment for core symptoms associated with these disorders. In this review, we outline oxytocin's clinical pharmacology, safety considerations, and results in recent clinical trials. We propose that oxytocin may be most beneficial in these populations if dosed in a dynamic regimen (PRN) and paired with social interventions.
本手稿综述了近期关于催产素及其在神经发育障碍中的应用的研究,这些神经发育障碍包括自闭症谱系障碍(ASD)和普拉德-威利综合征(PWS)。催产素参与社会认知、情感联系、母性行为、焦虑、食物动机和食欲亢进。虽然ASD和PWS的病理生理学涉及催产素系统异常,但临床试验显示,催产素作为治疗这些疾病相关核心症状的有效性存在不一致的结果。在本综述中,我们概述了催产素的临床药理学、安全性考量以及近期临床试验的结果。我们提出,如果采用动态给药方案(必要时)并结合社会干预措施,催产素可能对这些人群最为有益。